Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Futibatinib

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Taiho Oncology Europe Launches Lytgobi For Cholangiocarcinoma
    Taiho Oncology Europe Launches Lytgobi For Cholangiocarcinoma

    03 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-03/taiho-oncology-europe-announces-the-launch-of-lytgobi-futibatinib-in-the-united-kingdom-for-elig

    PHARMIWEB
    03 Dec 2025
    Share Share
    Taiho Pharma's Lytgobi (futibatinib) Receives Approval in Europe
    Taiho Pharma's Lytgobi (futibatinib) Receives Approval in Europe

    19 Oct 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/lytgobi-epar-medicine-overview_en.pdf

    EMA
    19 Oct 2023
    Share Share
    Boundless Bio Announces Agreement with Taiho Oncology to Evaluate LYTGOBI
    Boundless Bio Announces Agreement with Taiho Oncology to Evaluate LYTGOBI

    18 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230915424206/en

    BUSINESSWIRE
    18 Sep 2023
    Share Share
    Taiho's Lytgobi (futibatinib) Receives Approval in Europe
    Taiho's Lytgobi (futibatinib) Receives Approval in Europe

    18 Jul 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/lytgobi-epar-medicine-overview_en.pdf

    EMA
    18 Jul 2023
    Share Share
    EC Grants Conditional Marketing Authorization for Taiho's Lytgobi Tablets
    EC Grants Conditional Marketing Authorization for Taiho's Lytgobi Tablets

    05 Jul 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/european-commission-grants-conditional-marketing-authorization-for-taihos-lytgobi-tablets-for-the-treatment-of-adults-with-cholangiocarcinoma-301869543.html

    PR NEWSWIRE
    05 Jul 2023
    Share Share
    Chmp Issues Positive Opinion For Futibatinib For The Treatment
    Chmp Issues Positive Opinion For Futibatinib For The Treatment

    27 Apr 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chmp-issues-positive-opinion-for-futibatinib-for-the-treatment-of-adults-with-cholangiocarcinoma-301808851.html

    PR NEWSWIRE
    27 Apr 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.